The Phase 3 initiation for abdakibart in H1 2027 is the next major catalyst. Monitor for trial design details and enrollment timelines. The strong cash runway reduces near-term dilution risk, but the widening net loss and EPS miss may pressure the stock in the short term. Watch for analyst revisions and any updates on AVTX-010 IND filing.
Price Chart
Executive Summary
Avalo Therapeutics reported Q2 2026 results with a net loss of $36.4M ($0.83/share), missing consensus of $0.66. The company highlighted plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027 and advanced a next-generation anti-IL-1 antibody (AVTX-010) toward an IND. Cash and investments stood at $472.2M, providing runway into 2029. The pipeline progress and strong cash position are the key drivers, outweighing the earnings miss for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and investments of $472.2M as of June 30, 2026, expected to fund operations into 2029.
- Net loss of $36.4M for Q2 2026 vs $20.8M in Q2 2025; EPS of -$0.83 vs consensus -$0.66.
- Plans to initiate a registrational Phase 3 program for abdakibart in HS in the first half of 2027.
- Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1 antibody; IND submission planned for H1 2027.
- Appointed Ron Philip to the Board of Directors.
- Added to the Russell 2000 and Russell 3000 Indexes.
Financial Impact
Net loss widened by $15.6M YoY; EPS missed consensus by $0.17 (25.8% miss). Cash position strengthened to $472.2M from $82M at Q1 2026 end, reflecting the $431.3M May 2026 offering.
Risk Factors
- Clinical trial failure or delay in Phase 3 for abdakibart.
- Regulatory hurdles for AVTX-010 IND.
- Competition from other IL-1 inhibitors and HS therapies.
- Potential shareholder dilution from future financing needs despite current cash runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001534120-26-000048 |
| Document: avtx-20260806.htm | 0001534120-26-000048 |
| Document: 0001534120-26-000048-index-headers.html | 0001534120-26-000048 |
| Document: 0001534120-26-000048-index.html | 0001534120-26-000048 |
| Document: 0001534120-26-000048.txt | 0001534120-26-000048 |
| 8-K Data (Synthetic) | 0001534120-26-000048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access